Time filter

Source Type

Kuopio, Finland

Lesch H.P.,FKD Therapies | Lesch H.P.,Vision-1 | Lesch H.P.,University of Eastern Finland | Heikkila K.M.,Vision-1 | And 16 more authors.
Human Gene Therapy | Year: 2015

Large-scale vector manufacturing for phase III and beyond has proven to be challenging. Upscaling the process with suspension cells is increasingly feasible, but many viral production applications are still applicable only in adherent settings. Scaling up the adherent system has proven to be troublesome. The iCELLis® disposable fixed-bed bioreactors offer a possible option for viral vector manufacturing in large quantities in an adherent environment. In this study, we have optimized adenovirus serotype 5 manufacturing using iCELLis Nano with a cultivation area up to 4 m2. HEK293 cell cultivation, infection, and harvest of the virus (by lysing the cells inside the bioreactor) proved possible, reaching total yield of up to 1.6×1014 viral particles (vp)/batch. The iCELLis 500 is designed to satisfy demand for large-scale requirements. Inoculating a large quantity of cell mass into the iCELLis 500 was achieved by first expanding the cell mass in suspension. Upscaling the process into an iCELLis 500/100 m2 cultivation area cassette was practical and produced up to 6.1×1015 vp. Flask productivity per cm2 in iCELLis Nano and iCELLis 500 was in the same range. As a conclusion, we showed for the first time that iCELLis 500 equipment has provided an effective way to manufacture large batches of adenoviral vectors. © 2015, Mary Ann Liebert, Inc. Source

Discover hidden collaborations